Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GeneDx Holdings (WGS) Revenue (2020 - 2025)

Historic Revenue for GeneDx Holdings (WGS) over the last 6 years, with Q3 2025 value amounting to $116.7 million.

  • GeneDx Holdings' Revenue rose 5186.28% to $116.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $402.2 million, marking a year-over-year increase of 5050.44%. This contributed to the annual value of $305.4 million for FY2024, which is 5079.04% up from last year.
  • Latest data reveals that GeneDx Holdings reported Revenue of $116.7 million as of Q3 2025, which was up 5186.28% from $102.7 million recorded in Q2 2025.
  • GeneDx Holdings' 5-year Revenue high stood at $116.7 million for Q3 2025, and its period low was $36.2 million during Q2 2022.
  • Moreover, its 5-year median value for Revenue was $61.4 million (2022), whereas its average is $66.4 million.
  • As far as peak fluctuations go, GeneDx Holdings' Revenue skyrocketed by 9276.95% in 2022, and later crashed by 3596.01% in 2023.
  • Over the past 5 years, GeneDx Holdings' Revenue (Quarter) stood at $57.8 million in 2021, then increased by 6.14% to $61.4 million in 2022, then dropped by 6.41% to $57.4 million in 2023, then surged by 66.57% to $95.6 million in 2024, then rose by 22.07% to $116.7 million in 2025.
  • Its Revenue was $116.7 million in Q3 2025, compared to $102.7 million in Q2 2025 and $87.1 million in Q1 2025.